HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Dasatinib | Sprycel | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Acalabrutinib | Calquence | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2017 | In Use | |||
NA | Anastrozole | Arimidex | 0.5 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | In Use | ||||
N/A | Ensartinib | ENSACOVE | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, ROS1, MET | Yes | 2025 | In Use | |||
Mobocertinib | Exkivity | 40mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2021 | In Use | ||||
NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
N/A | Taletrectinib | IBTROZI | 272mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Yes | 2025 | In Use | |||
NA | Imatinib mesylate | Gleevec | 400 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | In Use | |||
NA | Abemaciclib | Verzenio | 50 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Avapritinib | Ayvakit | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
NA | Aprepitant | Emend | 80 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Dutasteride | Avodart | 0.5mg | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Yes | 2002 | In Use | |||
NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
NA | Belumosudil | Rezurock | 200mg | Chemotherapy | Rho Kinase Inhibitor | ROCK1, ROCK2 | Yes | 2021 | In Use | |||
N/A | Avutometinib potassium and defactinib hydrochloride | AVMAPKI FAKZYNJA CO-PACK | 0.8mg and 200mg | Chemotherapy | MEK Inhibitor, Tyrosine Kinase Inhibitor | MEK1/2, ERK1/2, KRAS | Yes | 2025 | In Use | |||
NA | Anagrelide | Agrylin | 0.5mg | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Yes | 1997 | In Use | |||
NA | Axitinib | Axitinib | 1 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
NA | Bexarotene | Targretin | 75mg | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | Yes | 2014 | In Use | |||
Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
NA | Avapritinib | Ayvakit | 25mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
NA | Dacomitinib | Vizimpro | 15mg, 30mg, 45mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2018 | In Use | |||
NA | Cysteamine Bitartrate | Cystagon | 50mg, 150mg | Chemotherapy | Cystine-Depleting Agent | Yes | 1994 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.